Results 131 to 140 of about 22,112 (211)

Enhancing Specificity, Precision, Accessibility, Flexibility, and Safety to Overcome Traditional CRISPR/Cas Editing Challenges and Shape Future Innovations

Advanced Science, Volume 12, Issue 28, July 24, 2025.
CRISPR/Cas9, while transformative, faces challenges in specificity, precision, delivery, accessibility, flexibility, and safety. This review addresses these limitations by highlighting strategies to reduce off‐target effects, exploring HDR‐based and alternative editing approaches, and evaluating advanced delivery mechanisms.
Muna Alariqi, Mohamed Ramadan, Lu Yu, Fengjiao Hui, Amjad Hussain, Xiaofeng Zhou, Yu Yu, Xianlong Zhang, Shuangxia Jin   +8 more
wiley   +1 more source

Static magnetic field promotes the doxorubicin toxicity effects on osteosarcoma cells. [PDF]

Sci Rep
Rajabi F, Hajipour-Verdom B, Abdolmaleki P.   +2 more
europepmc   +1 more source

Maximizing Efficacy of Cancer Nanovaccines and Immune Cells Landscape in Responders and Non‐Responders to Immunotherapy

Advanced Science, EarlyView.
To maximize the efficacy of cancer vaccines, adjuvants, collection, lysis, purification, oxidation, loading sites, and sizes, etc., are investigated. The optimized cancer nanovaccines loading whole tumor antigens can cure all or most tumor‐bearing mice in multiple mouse cancer models.
Xiangxiang Xu, Lu Diao, Jin Wang, Ao Zhu, Xianlan Chen, Yan Zheng, Yuhan Liu, Kang Hu, Jiashan Zhu, Cheng Ding, Chang Li, Yunzhi Pan, Jun Zhao, Mi Liu   +13 more
wiley   +1 more source

Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer. [PDF]

Cancer Immunol Res
Schwarz E, Savardekar H, Zelinskas S, Mouse A, Lapurga G, Lyberger J, Rivaldi A, Ringwalt EM, Miller KE, Yu L, Behbehani GK, Cripe TP, Carson WE.   +12 more
europepmc   +1 more source

Evaluation of attenuated tumor antigens and the implications for peptide-based cancer vaccine development [PDF]

, 2017
Berry, J. S, Clifton, G. T, Greene, J. M, Hale, D. F, Hardin, M. O, Herbert, G. S, Jackson, D. O, Peoples, G. E, Trappey, A. F, Vreeland, T. J   +9 more
core   +2 more sources

Small RNA Toxin‐Assisted Evolution of GC‐Preferred ErCas12a for Enhanced Genome Targeting Range

Advanced Science, EarlyView.
ErCas12a is engineered to target GC‐rich PAMs using a small RNA toxin‐aided positive screening system. The resulting variant, enErCas12a, exhibits an expanded PAM profile and facilitates efficient gene editing in both bacterial and mammalian cells, while preserving high targeting specificity for both canonical and non‐canonical PAM targets.
Zehua Chen, Junyuan Xue, Ziying Wang, Jinyuan Sun, Yinglu Cui, Tong Zhu, Huaiyi Yang, Ming Li, Bian Wu   +8 more
wiley   +1 more source

Radiation therapy results in preferential tumor antigen-specific lymphodepletion in head and neck cancer. [PDF]

Nat Commun
Zenga J, Awan MJ, Frei A, Foeckler J, Kuehn R, Kasprzak J, Massey B, Bruening J, Akakpo K, Shukla M, Wong SJ, Mathison AJ, Wendt Andrae J, Hunt B, Puzyrenko A, Jin VX, Memon AA, Villarreal Espinosa O, Chen F, Shaheduzzaman M, Kearl T, Hematti P, Himburg HA.   +22 more
europepmc   +1 more source

Mechanism and modification of rejection of heterografts between divergent species. [PDF]

, 1970
Amemiya, H, Boehmig, HJ, Coburg, AJ, Dixon, FJ, Giles, GR, Hathaway, WE, Lilly, J, Starzl, TE, Takagi, H, Wilson, CB   +9 more
core  

Localized Delivery of the mRNAs Encoding CD47 Inhibitor and Interleukins 12, 15, and 21 Elicits Robust Antitumor Immunity

Advanced Science, EarlyView.
The co‐delivery of mRNAs encoding a CD47 inhibitor and a cytokine cocktail (interleukins 12, 15, and 21) via lipid nanoparticles enables effective localized immunotherapy. This strategy not only suppresses tumor progression but also enhances type 1 conventional dendritic cell (cDC1) differentiation and activates CD8+ T cells, thereby inducing robust ...
Tao Jiang, Shuaiyang Jing, Haojun Li, Bao Xiao, Jiahui Jin, Xiu Sun, Juan Wang, Jing Liang, Tongze Cai, Huili Hu, Meilan Wei, Xuanrui Zhong, Yang Ji, Peng George Wang, Jianlong Zhou   +14 more
wiley   +1 more source

Luteolin as an adjuvant effectively enhanced the efficacy of adoptive tumor-specific CTLs therapy. [PDF]

BMC Cancer
Lai Z, Pang Y, Zhou Y, Chen L, Zheng K, Yuan S, Wang W.   +6 more
europepmc   +1 more source